MA51004A - Nouveaux analogues spirobicycliques - Google Patents
Nouveaux analogues spirobicycliquesInfo
- Publication number
- MA51004A MA51004A MA051004A MA51004A MA51004A MA 51004 A MA51004 A MA 51004A MA 051004 A MA051004 A MA 051004A MA 51004 A MA51004 A MA 51004A MA 51004 A MA51004 A MA 51004A
- Authority
- MA
- Morocco
- Prior art keywords
- spirobicyclic
- analogues
- new
- spirobicyclic analogues
- new spirobicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762596441P | 2017-12-08 | 2017-12-08 | |
EP18163867 | 2018-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51004A true MA51004A (fr) | 2020-10-14 |
Family
ID=64664279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051004A MA51004A (fr) | 2017-12-08 | 2018-12-06 | Nouveaux analogues spirobicycliques |
Country Status (12)
Country | Link |
---|---|
US (3) | US11059850B2 (fr) |
EP (1) | EP3720865B1 (fr) |
JP (1) | JP7352544B2 (fr) |
KR (1) | KR20200097280A (fr) |
CN (1) | CN111479817B (fr) |
AU (1) | AU2018379456B2 (fr) |
BR (1) | BR112020010815A2 (fr) |
CA (1) | CA3084449A1 (fr) |
IL (1) | IL275129B2 (fr) |
MA (1) | MA51004A (fr) |
MX (1) | MX2020005944A (fr) |
WO (1) | WO2019110734A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
US11059850B2 (en) * | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
CA3134779A1 (fr) * | 2019-03-25 | 2020-10-01 | California Institute Of Technology | Inhibiteurs de prmt5 et leurs utilisations |
TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用prmt5抑制劑治療癌症之方法 |
CA3138349A1 (fr) * | 2019-06-12 | 2020-12-17 | Jonas VERHOEVEN | Nouveaux intermediaires spirobicycliques |
CA3166735A1 (fr) * | 2020-01-07 | 2021-07-15 | Pfizer Inc. | Inhibiteur de prmt5 destine a etre utilise dans une methode de traitement du psoriasis et d'autres affections auto-immunes |
CA3176912A1 (fr) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Derives de piperidine-1-yl-n-pyridine-3-yl-2-oxoacetamide utiles pour le traitement des cancers deficients en mtap et/ou a accumulation de mta |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
EP0970342A1 (fr) * | 1997-03-13 | 2000-01-12 | Peter Spielberger | Etui pour armes legeres |
WO2003039523A2 (fr) | 2001-11-05 | 2003-05-15 | Exiqon A/S | Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha |
US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
CN1636009A (zh) | 2002-02-19 | 2005-07-06 | Cv医药有限公司 | A1 腺苷受体的部分和全促效药 |
US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
WO2005005450A1 (fr) | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | Procede de synthese d'un bisdinucleoside cyclique |
EP1694642A4 (fr) | 2003-12-19 | 2010-10-06 | Koronis Pharmaceuticals Inc | Heterocycles mutagenes |
EP1844062A2 (fr) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibiteurs d'adn-methyltransferase |
US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
US8962580B2 (en) | 2008-09-23 | 2015-02-24 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
WO2011075665A2 (fr) | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Composés promouvant la réplication des cellules bêta et méthodes d'utilisation de ces composés |
EP2646454B1 (fr) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci |
AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
CN103354808B (zh) | 2010-12-16 | 2016-08-10 | Abbvie公司 | 抗病毒化合物 |
EP2694524B1 (fr) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides |
US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
WO2014035140A2 (fr) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Composés et compositions pour la modulation de l'activité histone méthyltransférase |
US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
EP2935241A1 (fr) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2014145214A2 (fr) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibiteurs de prmt5 et leurs procédés d'utilisation |
EP3091984B1 (fr) | 2014-01-09 | 2020-04-22 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Benzoxazine substituée et composés associés |
US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
DK3164130T3 (da) | 2014-07-01 | 2019-10-28 | Millennium Pharm Inc | Heteroaryle forbindelser anvendelige som inhibatorer af sumo-aktiverende enzym |
CN107278205A (zh) | 2015-02-24 | 2017-10-20 | 辉瑞大药厂 | 用作抗癌药的取代的核苷衍生物 |
TW202321249A (zh) * | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
CN108884108B (zh) | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
WO2018065365A1 (fr) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
PE20190706A1 (es) | 2016-10-03 | 2019-05-17 | Janssen Pharmaceutica Nv | Analogos novedosos de carbanucleosidos sustituidos de sistema anular monociclico y bicicilo para su uso como inhibidores de prmt5 |
MA47594A (fr) | 2017-02-27 | 2020-01-01 | Janssen Pharmaceutica Nv | Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5 |
US11059850B2 (en) * | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
-
2018
- 2018-12-06 US US16/769,793 patent/US11059850B2/en active Active
- 2018-12-06 BR BR112020010815-4A patent/BR112020010815A2/pt unknown
- 2018-12-06 IL IL275129A patent/IL275129B2/en unknown
- 2018-12-06 CA CA3084449A patent/CA3084449A1/fr active Pending
- 2018-12-06 JP JP2020530597A patent/JP7352544B2/ja active Active
- 2018-12-06 MX MX2020005944A patent/MX2020005944A/es unknown
- 2018-12-06 AU AU2018379456A patent/AU2018379456B2/en active Active
- 2018-12-06 WO PCT/EP2018/083808 patent/WO2019110734A1/fr unknown
- 2018-12-06 CN CN201880078974.8A patent/CN111479817B/zh active Active
- 2018-12-06 EP EP18816013.9A patent/EP3720865B1/fr active Active
- 2018-12-06 KR KR1020207017711A patent/KR20200097280A/ko not_active Application Discontinuation
- 2018-12-06 MA MA051004A patent/MA51004A/fr unknown
-
2021
- 2021-06-10 US US17/344,261 patent/US11702441B2/en active Active
-
2023
- 2023-05-18 US US18/320,071 patent/US20230303612A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL275129B1 (en) | 2023-06-01 |
BR112020010815A2 (pt) | 2020-11-10 |
EP3720865B1 (fr) | 2024-03-13 |
AU2018379456B2 (en) | 2022-11-24 |
KR20200097280A (ko) | 2020-08-18 |
RU2020122212A (ru) | 2022-01-10 |
US20230303612A1 (en) | 2023-09-28 |
JP7352544B2 (ja) | 2023-09-28 |
MX2020005944A (es) | 2020-08-24 |
EP3720865C0 (fr) | 2024-03-13 |
US20200369707A1 (en) | 2020-11-26 |
CN111479817A (zh) | 2020-07-31 |
JP2021505582A (ja) | 2021-02-18 |
RU2020122212A3 (fr) | 2022-01-10 |
IL275129A (en) | 2020-07-30 |
CA3084449A1 (fr) | 2019-06-13 |
CN111479817B (zh) | 2023-03-21 |
US20210380627A1 (en) | 2021-12-09 |
EP3720865A1 (fr) | 2020-10-14 |
WO2019110734A1 (fr) | 2019-06-13 |
US11059850B2 (en) | 2021-07-13 |
IL275129B2 (en) | 2023-10-01 |
US11702441B2 (en) | 2023-07-18 |
AU2018379456A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3731771T3 (da) | V462033dk00 | |
DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
MA51004A (fr) | Nouveaux analogues spirobicycliques | |
CL2018000524S1 (es) | Golilla | |
DK3351526T3 (da) | Diisopentylterephthalat | |
MA45430A (fr) | Analogues de célastrol | |
DK3568655T3 (da) | Rekuperator | |
DK3571580T3 (da) | Load-logical-and-shift-guarded-instruktion | |
DK3445742T3 (da) | Krystallin tapentadolphosphat | |
DK3612237T3 (da) | Genterapi | |
DK3568506T3 (da) | Offeranode | |
DK3576686T3 (da) | Brokbind | |
DK3676276T3 (da) | Spirothietannukleosider | |
DK3576718T3 (da) | Pastil | |
FI11704U1 (fi) | Liittopuujärjestely | |
DK3510051T3 (da) | Carboxylalkylchitosan | |
DK3642136T3 (da) | Veksellad | |
DK3395159T3 (da) | Ballepresse | |
ES1205411Y (es) | Maleta-Gaveta | |
ES1198359Y (es) | Columbario | |
FI11529U1 (fi) | Ontelolaatan kannake | |
ES1145433Y (es) | Jamonero multiposicionable | |
DK3645955T3 (da) | Buffertank | |
MA47846A (fr) | Nouveaux polyimino-cétoaldéhydes | |
DK3401461T3 (da) | Falsetagtegl |